关注并星标CPHI制药在线2025年6月2日,翰森制药与再生元(Regeneron)达成一项重磅许可协议,翰森将其在研的GLP-1/GIP双受体激动剂HS-20094的全球独占许可(不含中国内地、中国中国香港及中国中国澳门)权利授予再生元。这一交易瞬间吸引了全球医药行业的目光,其背后的价值和潜力究竟几何?从交易条款来看,翰森制药收获颇丰。8000万美元的首付款,是再生元对HS-20094潜力的初步...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.